Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 浙江亚太药业股份有限公司是一家致力于化学制剂类药物的研发、生产、销售,以基层医疗市场为主的企业.公司研发中心被认定为浙江省级高新技术研究开发中心,公司先后拥有国家级新产品1 个、国家火炬计划项目1 项、浙江省高新技术产品6 个.罗红霉素胶囊、头孢氨苄胶囊、阿奇霉素分散片及注射用阿奇霉素为本公司的主导产品,其中2007年罗红霉素胶囊产量位居全国第一,头孢氨苄胶囊产量位居全国第四、阿奇霉素分散片产量位居全国第二。 | ||||||||||||||||||||||||
Main Business | 医药制造业务,包括化学制剂、化学原料药的研发、生产和销售。 | ||||||||||||||||||||||||
Legal Representative | 岑建维 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 徐炜 | ||||||||||||||||||||||||
Solicitors | 国浩律师(杭州)事务所 | ||||||||||||||||||||||||
Auditors | 天健会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 0575-84810101 | ||||||||||||||||||||||||
Fax No | 0575-84810101 | ||||||||||||||||||||||||
Website | www.ytyaoye.com | ||||||||||||||||||||||||
ytdsh@ytyaoye.com | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 16/03/2010 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ -0.020 | ||||||||||||||||||||||||
DPS(RMB)* | -- | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 0.725 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 2.051B |
Only Chinese content is avaliable | |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |